Improving Heart Function
Partager
Advancing trans-disciplinary innovation in heart failure drugs & device solutions to improve patient care.
25/09/2026
NEW PRE-COURSE | Cardiogenic shock: "Eyes on the pump" 🫀
Join iHF and PCR MCS Focus Group on 21 November in London, ahead of PCR LondonValves .
Explore mechanical circulatory support decision-making, device selection, complications, escalation and weaning through challenging cases and expert discussions.
📅 21 November 2026📍 London
Discover the programme → https://www.pcronline.com/Network/Pre-course-on-cardiogenic-shock-eyes-on-the-pump
11/09/2026
Recognising coronary microvascular dysfunction in HFpEF is only the first step.
What comes next? 🤔
👉 Join this free live iHF Webinar to explore diagnosis, patient selection and the evidence behind tailored treatment strategies through case-based discussion.
Coordinators J. Bartunek and M. Kaluzna-Oleksy will be joined by F. Andreotti, A. Gonzalez Miqueo, S. Verheye and E. Gallinoro.
📅 Tuesday 29 September, 5:30pm (UTC+2)
🔗 Register for free: https://www.iheartfunction.com/webinars/hfpef-and-microvascular-dysfunction-mechanistic-understanding-tailored-treatment-strategy
19/08/2026
🔎 Tricuspid Regurgitation in Heart Failure: when is it time to act?
Join Marianna Adamo, Marta Sitges, Marina Urena, Giuseppe Rosano and Mirjam Wild for a practical expert discussion covering:
- When to suspect TR progression
- When to worry about right-heart deterioration
- When to consider referral and intervention
📅 Thursday 3 September 2026 I 5:00 PM (UTC+2)
💻 Online I Free registration
👉 Register now: https://brnw.ch/21x539b
Organized in collaboration with the PCRonline Tricuspid Focus Group.
14/07/2026
🔎 Could home-based decongestion redefine the management of worsening heart failure?
Presented at HFA 2026, the SUBCUT-HF II trial explores whether early discharge with an ambulatory, patient-managed subcutaneous furosemide pump can optimize heart failure care.
In this new Trial Review, Jan Biegus reviews the evidence and explores the potential of this innovative home-based decongestion strategy for patients with worsening heart failure.
Watch the full review: https://brnw.ch/21x482J
SUBCUT HF II - Trial review Jan Biegus reviews the SUBCUT-HF II trial, evaluating whether early discharge combined with an ambulatory subcutaneous furosemide pump safely improves out-of-hospital days for heart failure patients compared to standard care.
👀 Do you remember the case of a 39-year-old patient presented with a late STEMI complicated by severe biventricular dysfunction and a non-restrictive ventricular septal defect (VSD) rapidly requiring peripheral VA-ECMO and IABP support?
Faced with this life-threatening scenario, opinion was highly divided among respondents. Discover now the Heart Team's strategy to manage this major mechanical complication.
👉 Read the Part 2: https://brnw.ch/21x41ja
Share your thoughts in the comments!
🫀 or ? The answer isn't always straightforward.
For patients with and chronic coronary syndromes, choosing the optimal revascularisation strategy goes far beyond coronary anatomy.
In this excerpt from our last iHF Webinar, experts discuss the respective roles of CABG and PCI, the importance of achieving complete revascularisation, and why every complex case should be reviewed by a multidisciplinary Heart Team.
🎥 Watch the full webinar on the iHF website to explore the complete clinical case and the latest evidence guiding decision-making: https://www.iheartfunction.com/webinars/hfref-and-chronic-coronary-syndromes-guided-directed-medical-therapy-optimal
🎥 Missed our latest webinar? The replay is now available!
Catch up with this free iHF webinar on HFrEF and chronic coronary syndromes, featuring a multidisciplinary Heart Team discussion based on a real-world patient case.
Gain practical insights into:
- Selecting patients with HFrEF and CAD who may benefit from revascularisation
- Choosing between PCI and CABG
- Optimising guideline-directed medical therapy following revascularisation
🔗 Watch the free replay: https://brnw.ch/21x3NA9
30/06/2026
🫀 Can therapy redefine treatment for a specific phenotype?
Published in Circulation, the PRAISE-MR trial explores whether sacubitril/valsartan can improve haemodynamics, exercise capacity and atrial functional mitral regurgitation in patients with HFpEF.
In this new Journal Club, Jolie Bruno reviews the study, highlights its key findings, and discusses what they could mean for the management of HFpEF in clinical practice.
📖 Read here:
https://www.iheartfunction.com/news/angiotensin-receptor-neprilysin-inhibitor-heart-failure-preserved-ejection-fraction
🫀 Post-MI ventricular septual rupture: a critical trans-disciplinary case
A 39-year-old patient with no medical history presented with a late STEMI, severe biventricular dysfunction, and a non-restrictive ventricular septal defect (VSD).
Despite urgent PCI and IABP support, his condition quickly deteriorated, with severe lactic acidosis and pulmonary oedema. Intubated and transferred to a hub centre, he required peripheral VA-ECMO rescue.
How would you manage this post-MI mechanical complication?
👉 Read the case and vote: https://brnw.ch/21x3Eej
How can GDMT and MCS devices optimize the management of patients with advanced heart failure?
🎥 Hear key insights from Daniel Burkhoff and Alexandre Mebazaa, and catch up with this 2026 case-based session on our website.
🔗 Watch the replay: https://brnw.ch/21x3xVS
Cliquez ici pour réclamer votre Listage Commercial.
Contacter l'école
Site Web
Adresse
19-21, Rue Dumont D'Urville
Paris
75016